Last updated: 2026-09-16 09:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Alvotech (ALVO) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $5.34, with a market capitalisation of $1.80B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.94 to $9.25. This page covers its latest market performance, valuation, price trends and company information.
$1.80B | |
$5.06 | |
$18.00 | |
$2.94 | |
$5.02 | |
35.02K | |
933.96K | |
-- | |
$9.25 | |
$2.94 | |
-- | |
-- |
Alvotech (ALVO) is trading at $5.34 in pre-market trading as of 2026-09-16 08:47:00, up 6.35% ($0.32) from the previous close of $5.02
Pre-market trading shows how investors are pricing ALVO before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Alvotech (ALVO) moved from $5.32 to $5.34, representing a gain of 0.36% ($0.02).
The stock traded between $4.90 and $5.40 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 604.76 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38.0%
ALVO is currently trading at $5.34, placing it 38.0% of the way from its 52-week low of $2.94 to its 52-week high of $9.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
| Employees | 1460 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alvotech (ALVO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.